Posted 1/31/2024, 12:10:00 AM
Vertex Pain Drug Meets Primary Endpoint in Phase 3 Trial, But Falls Short on Secondary Goal
- Vertex's pain drug VX-548 met primary endpoint in phase 3 trial for treating acute pain
- The drug showed ability to notably reduce pain over a 48-hour period
- However, it failed to meet secondary endpoint of reducing pain more than acetaminophen and hydrocodone
- VX-548 demonstrated favorable safety and tolerability profile in the trial
- Vertex plans to file for FDA approval soon, citing Breakthrough and Fast Track Designations